Last reviewed · How we verify
placebo like asacol
This is a placebo formulation designed to mimic Asacol (mesalamine) for use in clinical trials or comparative studies.
This is a placebo formulation designed to mimic Asacol (mesalamine) for use in clinical trials or comparative studies. Used for Clinical trial control for inflammatory bowel disease (ulcerative colitis, Crohn's disease).
At a glance
| Generic name | placebo like asacol |
|---|---|
| Sponsor | Tehran University of Medical Sciences |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
As a placebo, this product contains no active pharmaceutical ingredient and is intended to be indistinguishable from Asacol in appearance and administration. It is used in blinded clinical trials to control for placebo effects when evaluating the efficacy of mesalamine in inflammatory bowel disease. The placebo allows researchers to isolate the true therapeutic benefit of the active drug from psychological and expectation-based improvements.
Approved indications
- Clinical trial control for inflammatory bowel disease (ulcerative colitis, Crohn's disease)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo like asacol CI brief — competitive landscape report
- placebo like asacol updates RSS · CI watch RSS
- Tehran University of Medical Sciences portfolio CI